Richard Harmon, PeterSuzman,,
Miljenko Zuanic, David Kincade, and .... Pirkkal,
12 months hence...bliss=not. A bottle of Napa's best
+ entrees to ARGENT + FAS takes the day. Ariad will
be at $8 by labor day.
Ependymal cells are
news. If you're well read...you'll know why. Miljenko?
Genomics are hot and Hazeltine
bogarts the kliegs while Ariad, is patient....with cause.
Berger willing to fund the lab by whatever means
necessary to achieve stated goals
Rod Searling, your day be here. Ignorance
pervasive and persuasive.
Odds to no acknowledgement
of this post. Miljenko...Richard can't handle the
'wild west' eh? Marquez could.
High Noon For Gene Therapy The article focuses on
hemophilia, but a good read...and anything with Wilsonin
there catches my eye.http://www.signalsmag.com/"We are
now in the era of the adeno-associated virus (AAV).
This tiny virus, which can only replicate in the
presence of adenovirus (hence the name), seems ideal. It
infects both dividing and non-dividing cells; it causes
far less of an immune response than the adenovirus;
and it apparently integrates its DNA package into the
genome of host cells, leading to long-lasting
expression. And AAV does not cause any disease, as far as
anyone knows, so it appears safer than other viral
vectors."At had visions of selling a nice chunk of Magain
todayand grabbing another "third" of Ariad...but it was
not tobe. And what a shame...toward the end of the
sessionthere my shares were...10k of them dumped at 1
1/8th.Yup, I actually hold 20k shares of this puppy, nearly
aquarter of my stock holdings...I don't call the
portfolio"Mike's Microcap Madness" for nothing.Anyway, enough chit
chat...read the Signals article, itwill remind you of the
incredible challenges of gene therapy...but then go back and
read the pnas paperto cheer you up. That is what I
did. No, I wont be grabbing any additional shares, but
I still have high hopes for Ariad. High hopes at
high noon...Mad Dogs and Englishmen.
This board seems to have serious posters. I am
new to it. Because of BBBiotech's position I am
considering investing in Ariad. But it looks to be running
out of money, to put it bluntly. What does it have or
what will it have that might attract more money to it?
Is it, in short, headed for bankruptcy or for a new
infusion of funds? Is it worth a gamble?
Aurileano. Hands down kind sir, your last two
posts have placed you in the pantheon of biotech
contributors. There's no one here, or on Silicon Investor, who
matches your intelligence or your ability to express the
thrust of complex science so that all may understand.
The fact that a well respected poster on SI gave you,
a Yahoo participant, a direct link, without
comment, is a highly uncommon, and noteworthy event
Congratulations on your skills, knowledge, and
Now, if you please, answer a direct, though, perhaps
not simple, question: what is your opinion of Dr.
Berger? I'm well aware that biofreak2 and others are
dogmatically constrained. This dogma so often involves post
hoc rationalizations (the stock price has dropped
substantially therefore, the CEO must be incompetent) that any
talent in the CEO is masked.
Thus, if you or
anyone else replies, I expect one of your rational and
concise answers ...rather than the rumor-based nonsense
we see here............and especially on SI.
Your concern - and everyone else's for that
matter - should be significant indeed....if what you
stated were true. However, the paper did not study the
host's T cells but rather the role of the host's antigen
presenting cells (APCs). APCs present antigen in the proper
context to T cells in order to initiate an immune
response. The group eliminated APCs in the host and thereby
eliminated the ability of the donor T cells from responding.
This is a unique angle to address GvHD: most
approaches try to eliminate the donor T cells prior to
delivery of the BMT. Their data shows that such an
approach can work to greatly reduce the risk of
But eliminating (or, more accurately, blocking) a
(human) patient's APCs is a daunting and risky
task....and it has never been done before. The group has
shown that anti-APC antibodies will bind correctly to
mouse lymph nodes. But they haven't yet shown this
approach will block the APC function on these cells. So
the baseline conditions to establish a permissive
environment (void of APCs) in vivo has not been worked out in
mice...and thus is still a distant concept for human
application. There's also the problem that if the donor T
cells never 'see' host APC, then how will the help
fight recurrence of the cancer for which they were to
play an important role?
This work does not
effect the underlying scientific concept which Ariad is
basing its treatment approach. Donor T cells are still
the 'culprit' in GvHD...and it was always known that
host APC were providing the substrate to activate
The ARGENT system for GvHD has its own
problems. But as far as I know (important caveat), it's the
only one where the residual host APC remains intact
and the full complement donor T cells is provided.
Thus the patient, at least at the outset of treatment,
is receiving the most effective form BMT possible
It is my understanding that Ariad's approach to
GVHD is the elimination of DONOR T Cells after
transplantaion. The idea is that these cells are the culprit in
GVHD. The elimination of these cells would therefore
stop the progression of GVHD dead in its
A paper in the latest issue of SCIENCE (shlomchik
et al) suggests that the real culprit in GVHD is not
the DONOR T Cells, but rather the HOST T Cells.
Essentially their seminal finding is that blocking antigen
presentaion in Host cells is very protective against
My concern is that this may have negative
implications for Ariad's efforts in this area. In other words,
if it is the HOST cells that are responsible for the
disease, then would elimination of DONOR cells after
transplantation be an effective treatment.....
appreciate comments from people who may be a bit more
up-to-date on Ariad's animal work in this regard. Just how
effective has Ariad's approach to GVHD been in similar
animal models of the disease. I wasn't able to find much
in a quick PubMed search. An interesting experiment
would be to essentially repeat the work described in
this paper using donor T cells which have been
engineered with Ariad's technology.